Seasonal Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Seasonal Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A8188
Buy Now

Market Overview:

The seasonal allergic rhinitis market reached a value of US$ 10.5 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2023. Looking forward, IMARC Group expects the top 7 markets to reach US$ 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034.

Report Attribute
Key Statistics
Base Year 
2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 10.5 Billion
Market Forecast in 2034
US$ 14.1 Billion
Market Growth Rate 2024-2034
2.76%


The seasonal allergic rhinitis market has been comprehensively analyzed in IMARC's new report titled "Seasonal Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Seasonal allergic rhinitis, commonly called hay fever, refers to an allergic reaction that occurs in response to certain allergens present in the environment during specific seasons. It is characterized by inflammation of the nasal passages, resulting in various symptoms, such as sneezing, itching, a runny or stuffy nose, watery eyes, etc. Some individuals suffering from this ailment may also experience fatigue, coughing, sore throat, headache, nasal congestion, itchiness in the throat or ears, postnasal drip, impaired sleep cycle, etc. These symptoms can significantly impact daily activities and the overall quality of life. The diagnosis of seasonal allergic rhinitis is usually based on the patient's medical history, clinical signs, and physical examination. A healthcare provider may recommend skin prick tests to identify specific allergens that trigger the allergic reaction. Furthermore, radioallergosorbent testing is utilized to measure the amount of certain IgE antibodies in the blood that may be indicative of the disease. In some cases, a nasal provocation test is also required, which involves the introduction of a small amount of allergen directly into the nose to detect the cause of underlying symptoms.

Seasonal Allergic Rhinitis Market

The increasing cases of overactivation of the immune system which results in the release of histamine and other chemicals, thereby leading to an allergic response, are primarily driving the seasonal allergic rhinitis market. Additionally, the rising incidences of exposure to pollen from grasses, trees, weeds, etc., which cause inflammation and irritation in the airways, are also creating a positive outlook for the market. Moreover, the widespread adoption of intranasal corticosteroids, including fluticasone, budesonide, mometasone, etc., to minimize the symptoms of the ailment is further bolstering the market growth. Apart from this, the escalating application of effective medications, like antihistamines, since they work by blocking the histamine receptors and reducing the swelling of blood vessels in the nasal passages to alleviate discomfort among patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of allergy shots to treat this condition, owing to their several benefits, such as long-term relief, improved quality of life, and decreased need for other interventions, is expected to drive the seasonal allergic rhinitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the seasonal allergic rhinitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for seasonal allergic rhinitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the seasonal allergic rhinitis market in any manner.

Recent Developments:

  • In February 2024, Novartis disclosed that the US Food and Drug Administration (FDA) approved Xolair (omalizumab) to manage symptoms in people with moderate to severe seasonal allergic rhinitis. This therapy helps to lower blood eosinophil counts, which is associated with lower serum-free IgE levels in patients.
  • In August 2023, Inimmune Corporation initiated dosing of the first participant in its phase 1/1b First-in-Human clinical trial for INI-2004, a TLR4 agonist developed as a prospective treatment for seasonal allergic rhinitis.
  • In May 2023, Bausch Health Companies Inc. announced the launch of its new prescription treatment, RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) across Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis in adults, adolescents, and children aged 6 years and older. RYALTRIS is an intra-nasal spray that should not be taken orally, sprayed into the eyes or ears, or administered to the skin.
  • In May 2023, Altamira Therapeutics Ltd. revealed positive and statistically significant findings from a randomized controlled NASAR clinical trial of its Bentrio nasal spray in individuals suffering from seasonal allergic rhinitis. Bentrio nasal spray is a drug- and preservative-free gel emulsion that aids in protecting against dust mites and other airborne allergens like pollen.


Key Highlights:

  • About one-quarter (24.7%) of adults aged 18–44, 27.9% of adults aged 45–64, 26.4% of adults aged 65–74, and 21.7% of adults aged 75 and over had a seasonal allergy in 2021, as per the data of National Center for Health Statistics.
  • According to estimates regularly put forward, the prevalence of allergic respiratory diseases such as seasonal rhinitis has nearly doubled in industrialized countries in the past 20 years.
  • Non-Hispanic White adults (28.4%) were more likely to have a seasonal allergy compared with non-Hispanic Black (24.0%), Hispanic (18.8%), and non-Hispanic Asian (17.0%) adults.
  • The prevalence of seasonal allergic rhinitis in children groups were 16.1% in the city center compared to 6.7% in the rural area.
  • Over 26 percent of adults in the United States are affected by seasonal allergies, making it the most common allergic condition, as reported by the Centers for Disease Control and Prevention.
  • The Centers for Disease Control and Prevention researchers also found that seasonal allergies are more common among women (29.9%) than men (21.1%).


Drugs:

Astelin (azelastine hydrochloride) nasal spray is an antihistamine that inhibits sneezing, itching, runny nose, and numerous other nasal symptoms of seasonal allergies. The recommended dose of Astelin nasal spray in adults and children 12 years and older with seasonal allergic rhinitis is one or two sprays per nostril twice daily, whereas the dose in children 5 years to 11 years of age is one spray per nostril twice daily. Each spray of Astelin nasal spray delivers a volume of 0.137 mL solution containing 137 mcg of azelastine hydrochloride, which exhibits histamine H1-receptor antagonist activity in patients.

IRL-201104 is an under development immunomodulatory drug by Revolo Biotherapeutics for the treatment of seasonal allergic rhinitis. This therapeutic compound is a peptide derived from mycobacterium tuberculosis chaperonin 60.1 that reduces neutrophil invasion into the lung, thereby decreasing inflammation. It is administered through intravenous and subcutaneous routes to reset the immune response with the potential for inducing long-term disease remission.

REGN5713-5714-5715 is an investigational molecule to treat seasonal allergic rhinitis. The therapeutic substance consists of three human monoclonal antibodies, including REGN5713, REGN5714, REGN5715. It is delivered via intravenous and subcutaneous routes. The medicinal agent works by addressing pollen allergen Bet v 1 in patients.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the seasonal allergic rhinitis market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the seasonal allergic rhinitis market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current seasonal allergic rhinitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Astelin (Azelastine) Meda
Patanase (Olopatadine) Kyowa Kirin
Xyzal (Levocetirizine) Sanofi-Aventis/UCB
Qnasl (Beclometasone hydrofluoroalkane intranasal) Teva
Dymista (Azelastine/fluticasone propionate) Cipla/Meda
IRL 201104 Revolo Biotherapeutics
REGN5713 5714 5715 Regeneron Pharmaceuticals
Grass MATA MPL Allergy Therapeutics


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the seasonal allergic rhinitis market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the seasonal allergic rhinitis market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the seasonal allergic rhinitis market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (​2018-2034​) of seasonal allergic rhinitis across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of seasonal allergic rhinitis by age across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of seasonal allergic rhinitis by gender across the seven major markets?
  • How many patients are diagnosed (​2018-2034​) with seasonal allergic rhinitis across the seven major markets?
  • What is the size of the seasonal allergic rhinitis patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of seasonal allergic rhinitis?
  • What will be the growth rate of patients across the seven major markets?
     

Seasonal Allergic Rhinitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for seasonal allergic rhinitis drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the seasonal allergic rhinitis market?
  • What are the key regulatory events related to the seasonal allergic rhinitis market?
  • What is the structure of clinical trial landscape by status related to the seasonal allergic rhinitis market?
  • What is the structure of clinical trial landscape by phase related to the seasonal allergic rhinitis market?
  • What is the structure of clinical trial landscape by route of administration related to the seasonal allergic rhinitis market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Seasonal Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More